2023-08-29 12:36:29 ET
SPAC First Light Acquisition Corp. ( NYSE: FLAG ) shareholders have approved its planned merger with oncology drug developer Calidi Biotherapeutics.
First Light disclosed the vote in an SEC filing . It added that the company had entered into forward purchase and subscription agreements with Meteora Strategic Capital, Meteora Strategic Partners and Meteora Select Trading Opportunities Master. The SPAC did not indicate when the merger closing would take place.
First Light and Calidi announced the merger in January , with the deal estimating the enterprise value of the combined company at $335M.
After the closing, shares of the combined company are expected to trade on NYSE under the symbols CLDI.
More on First Light Acquisition Group, Inc.
- SPAC First Light adjourns Calidi merger vote to Aug. 28
- SPAC First Light adjourns meeting for Calidi merger vote to Aug. 24
- SPAC First Light to merge with oncology drug developer Calidi Biotherapeutics
- SPAC First Light CEO resigns, board extends deal deadline to March 14
For further details see:
First Light shareholders approve SPAC merger with Calidi Biotherapeutics